AGC Biologics, a global company involved in clinical and commercial development and manufacturing of therapeutic proteins, announced yesterday that it has named Kasper Moller as its new chief technical officer.
Moller will report to Patricio Massera, chief executive officer.
Moller joined AGC Biologics in 2006 as a scientist at the Copenhagen facility and has held the positions of principal scientist (2007) and department manager (2008) within Process Development. Beginning in 2010, Kasper led the Upstream Process Development teams and in 2011, he led process characterisation and validation activities. In 2013 - 2014, Kasper was appointed vice president of Process Development and in 2014 – 2017, Kasper was appointed vice president of Manufacturing. He has most recently served as the site head for AGC Biologics' Copenhagen facility and his role was expanded to include oversight of the Heidelberg, Germany site as well as Global Supply Chain Management and Global IT.
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees
GXO appointed to manage NHS England bowel cancer home testing kits